$CPRX Catalyst Pharmaceuticals Good Value

- Catalyst Pharmaceuticals, Inc. $CPRX focuses on developing therapies for rare neurological diseases - Firdapse has FDA approval for Lambert-Eaton myasthenic syndrome treatment - Consistent revenue growth, with a 82% increase in the most recent quarter - Promising pipeline of therapies targeting other rare neurological disorders - Positive net income and EBITDA growth indicate profitability and efficiency - Strong balance sheet with $137.6 million in cash and $3.5 million in debt - Positive operating cash flow and free cash flow growth - Recent earnings call was a beat, with next one scheduled for May 8th